Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07867626 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Study First Submitted
To evaluate the 12-month relapse free survival with weekly Decitabine/cedazuridine plus Venetoclax in AML maintenance after achieving composite CR (CR, CRi, CRh)
Trial Details
NCT Number NCT07867626
Lead Sponsor Rutgers, The State University of New Jersey
Conditions
(from sponsor)
Acute Myeloid Leukaemia (AML)
Related terms Leukemia, Myeloid, Acute
Enrollment 41 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov